Galderma raises 2026 outlook: Galderma stock trades at EUR 205.50

Published on 10/27/2026 at 10:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month sales reached USD 4.77 billion, up 25.10 percent. Galderma stock trades at EUR 205.50 on October 27, 2026, with CHF 44.3 billion market value.

Company growth drives the update

Galderma raised its 2026 sales-growth guidance to 22.50-23.50 percent on October 22, 2026.
First-nine-month sales reached USD 4.77 billion, up 25.10 percent at constant currency.
Galderma stock was trading at EUR 205.50 at 10:40 a.m. CET at Lang & Schwarz on October 27, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock (ISIN CH1335392721) was trading at EUR 205.50 at Lang & Schwarz at 10:40 a.m. CET on October 27, 2026. The company raised its full-year 2026 net sales growth guidance to 22.50-23.50 percent from 19.00-21.00 percent on October 22, 2026, according to Galderma.

Guidance moves higher

The upgraded outlook followed record net sales of USD 4.77 billion for the first nine months of 2026, an increase of 25.10 percent at constant currency from the same period of 2025. Third-quarter net sales rose 26.00 percent at constant currency to USD 1.63 billion from USD 1.29 billion, the company said in its October 22 release.

Therapeutic Dermatology supplied the sharpest product-category growth. Nine-month sales in that category rose 64.40 percent at constant currency to USD 1.35 billion, while Nemluvio sales reached USD 735.00 million, according to Galderma.

What does the growth mean?

The growth mix matters because the strongest contribution came from Therapeutic Dermatology, while Injectable Aesthetics and Dermatological Skincare also delivered double-digit expansion. The company confirmed full-year Core EBITDA margin guidance of 26.00 percent at constant currency and said the ZO Skin Health acquisition is expected to close in the fourth quarter of 2026 or early 2027.

Three dated company milestones

On April 22, 2026, shareholders approved a gross dividend of CHF 0.35 per dividend-bearing share, according to Galderma. On September 21, 2026, Galderma entered the Swiss Market Index. On October 22, 2026, nine-month sales reached USD 4.77 billion and the company lifted its growth guidance.

Upcoming development dates

Galderma targets the first quarter of 2027 to resubmit its U.S. biologics application for relabotulinumtoxinA, while topline results from a nemolizumab study in chronic pruritus of unknown origin are also expected in the first quarter of 2027, according to Galderma.

Barclays maintained a Buy rating and set a CHF 230.00 price target on October 23, 2026, according to Markets Insider. On SIX, the stock was last at CHF 189.80 at 11:32 a.m. CET on October 27, 2026, while market capitalization stood at CHF 44.3 billion and the 52-week range was CHF 136.30 to CHF 193.90. Galderma was included in the SMI on September 21, 2026. At Lang & Schwarz, Galderma was trading at EUR 205.50 on October 27, 2026 at 10:40 a.m. CET. The further course of trading is shown by the continuously updated real-time quote of Galderma stock.